Abstract
Advanced Parkinson’s disease (PD) is often complicated by the occurrence of dyskinesia, motor fluctuations and psychosis. To this day, few treatment options are available for each of these phenomena, and they are at times not effective or elicit adverse events, leaving some patients short of therapeutic options. We have recently shown that positive allosteric modulation of metabotropic 2 (mGlu2) receptors with the prototypical positive allosteric modulator (PAM) LY-487,379 is efficacious at alleviating both dyskinesia and psychosis-like behaviours (PLBs), while simultaneously enhancing the anti-parkinsonian action of L-3,4-dihydroxyphenylalanine (L-DOPA), in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset. Here, we assessed the effects of CBiPES, a mGlu2 PAM derived from LY-487,379, but with improved pharmacokinetic properties. Six MPTP-lesioned marmosets with reproducible dyskinesia and PLBs were administered L-DOPA in combination with vehicle or CBiPES (0.1, 1 and 10 mg/kg), after which their behaviour was rated. CBiPES 10 mg/kg reduced global dyskinesia by 60% (P < 0.0001), while peak dose dyskinesia was reduced by 66% (P < 0.001), compared to L-DOPA/vehicle. CBiPES 10 mg/kg also diminished global PLBs by 56% (P < 0.0001), while peak dose PLBs were reduced by 64% (P < 0.001), compared to L-DOPA/vehicle. Lastly, CBiPES enhanced the anti-parkinsonian action of L-DOPA, by reducing global parkinsonian disability by 43% (P < 0.01), compared to L-DOPA/vehicle. Our results provide further evidence that mGlu2 positive allosteric modulation may be an approach that could be efficacious for the treatment of dyskinesia, psychosis and motor fluctuations in PD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
Available upon written request to the corresponding author.
References
Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA (1993) Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 329(3):162–167. https://doi.org/10.1056/NEJM199307153290303
Ballanger B, Strafella AP, van Eimeren T, Zurowski M, Rusjan PM, Houle S, Fox SH (2010) Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 67(4):416–421. https://doi.org/10.1001/archneurol.2010.35
Beaudry F, Huot P (2020) The MPTP-lesioned marmoset model of Parkinson’s disease: proposed efficacy thresholds that may potentially predict successful clinical trial results. J Neural Transm (Vienna) 127(10):1343–1358. https://doi.org/10.1007/s00702-020-02247-2
Blanpied TA, Clarke RJ, Johnson JW (2005) Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci 25(13):3312–3322. https://doi.org/10.1523/JNEUROSCI.4262-04.2005
Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt MH, Chirilineau D, Stocchi F, Lucini V, Giuliani R, Forrest E, Rice P, Anand R, Study 018 Investigators (2014) Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s disease. Mov Disord 29(10):1273–1280. https://doi.org/10.1002/mds.25961
Cho SS, Strafella AP, Duff-Canning S, Zurowski M, Vijverman AC, Bruno V, Aquino CC, Criaud M, Rusjan PM, Houle S, Fox SH (2017) The relationship between serotonin-2A receptor and cognitive functions in nondemented Parkinson’s disease patients with visual hallucinations. Mov Disord Clin Pract 4(5):698–709. https://doi.org/10.1002/mdc3.12466
Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C (2014) Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 383(9916):533–540. https://doi.org/10.1016/S0140-6736(13)62106-6
Delille HK, Becker JM, Burkhardt S, Bleher B, Terstappen GC, Schmidt M, Meyer AH, Unger L, Marek GJ, Mezler M (2012) Heterocomplex formation of 5-HT2A-mGlu2 and its relevance for cellular signaling cascades. Neuropharmacology 62(7):2184–2191. https://doi.org/10.1016/j.neuropharm.2012.01.010
DeLong MR, Wichmann T (2007) Circuits and circuit disorders of the basal ganglia. Arch Neurol 64(1):20–24. https://doi.org/10.1001/archneur.64.1.20
Fell MJ, Flik G, Dijkman U, Folgering JH, Perry KW, Johnson BJ, Westerink BH, Svensson KA (2015) Glutamatergic regulation of brain histamine neurons: in vivo microdialysis and electrophysiology studies in the rat. Neuropharmacology 99:1–8. https://doi.org/10.1016/j.neuropharm.2015.05.034
Fell MJ, Katner JS, Johnson BG, Khilevich A, Schkeryantz JM, Perry KW, Svensson KA (2010) Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute ketamine challenge. Neuropharmacology 58(3):632–639. https://doi.org/10.1016/j.neuropharm.2009.11.014
Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P, Bi-Park 1 investigators (2016) Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol 15(2):154–165. https://doi.org/10.1016/S1474-4422(15)00336-1
Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, Coelho M, Sampaio C, Movement Disorder Society Evidence-Based Medicine C (2018) International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord 33(8):1248–1266. https://doi.org/10.1002/mds.27372
Fox SH, Visanji N, Reyes G, Huot P, Gomez-Ramirez J, Johnston T, Brotchie JM (2010) Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson’s disease. Can J Neurol Sci 37(1):86–95
Fox SH, Visanji NP, Johnston TH, Gomez-Ramirez J, Voon V, Brotchie JM (2006) Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease. Arch Neurol 63(9):1343–1344. https://doi.org/10.1001/archneur.63.9.1343
French Clozapine Parkinson Study Group (1999) Clozapine in drug-induced psychosis in Parkinson’s disease. The French Clozapine Parkinson Study Group. Lancet 353(9169):2041–2042. https://doi.org/10.1136/jnnp.2003.029868
Fribourg M, Moreno JL, Holloway T, Provasi D, Baki L, Mahajan R, Park G, Adney SK, Hatcher C, Eltit JM, Ruta JD, Albizu L, Li Z, Umali A, Shim J, Fabiato A, MacKerell AD Jr, Brezina V, Sealfon SC, Filizola M, Gonzalez-Maeso J, Logothetis DE (2011) Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell 147(5):1011–1023. https://doi.org/10.1016/j.cell.2011.09.055
Frouni I, Hamadjida A, Kwan C, Bedard D, Nafade V, Gaudette F, Nuara SG, Gourdon JC, Beaudry F, Huot P (2019) Activation of mGlu2/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism. Neuropharmacology 158:107725. https://doi.org/10.1016/j.neuropharm.2019.107725
Galici R, Jones CK, Hemstapat K, Nong Y, Echemendia NG, Williams LC, de Paulis T, Conn PJ (2006) Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J Pharmacol Exp Ther 318(1):173–185. https://doi.org/10.1124/jpet.106.102046
Gonzalez-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, Lopez-Gimenez JF, Zhou M, Okawa Y, Callado LF, Milligan G, Gingrich JA, Filizola M, Meana JJ, Sealfon SC (2008) Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452(7183):93–97. https://doi.org/10.1038/nature06612
Hamadjida A, Nuara SG, Bedard D, Frouni I, Kwan C, Gourdon JC, Huot P (2018a) Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset. Naunyn Schmiedebergs Arch Pharmacol 391(12):1339–1345. https://doi.org/10.1007/s00210-018-1549-6
Hamadjida A, Nuara SG, Bedard D, Gaudette F, Beaudry F, Gourdon JC, Huot P (2018b) The highly selective 5-HT2A antagonist EMD-281,014 reduces dyskinesia and psychosis in the l-DOPA-treated parkinsonian marmoset. Neuropharmacology 139:61–67. https://doi.org/10.1016/j.neuropharm.2018.06.038
Hamadjida A, Nuara SG, Gourdon JC, Huot P (2018c) The effect of mianserin on the severity of psychosis and dyskinesia in the parkinsonian marmoset. Prog Neuropsychopharmacol Biol Psychiatry 81:367–371. https://doi.org/10.1016/j.pnpbp.2017.09.001
Hamadjida A, Nuara SG, Gourdon JC, Huot P (2018d) Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson’s disease. J Neural Transm (Vienna) 125(9):1355–1360. https://doi.org/10.1007/s00702-017-1830-8
Hamadjida A, Nuara SG, Veyres N, Frouni I, Kwan C, Sid-Otmane L, Harraka MJ, Gourdon JC, Huot P (2017) The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset. Psychopharmacology 234(6):905–911. https://doi.org/10.1007/s00213-017-4530-z
Hamadjida A, Sid-Otmane L, Kwan C, Frouni I, Nafade V, Bedard D, Gagnon D, Wallman MJ, Rouillard C, Parent A, Parent M, Huot P (2020) The highly selective mGlu2 receptor positive allosteric modulator LY-487,379 alleviates l-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease. Eur J Neurosci. https://doi.org/10.1111/ejn.14679
Heinonen EH, Myllyla V (1998) Safety of selegiline (deprenyl) in the treatment of Parkinson’s disease. Drug Saf 19(1):11–22. https://doi.org/10.2165/00002018-199819010-00002
Hely MA, Morris JG, Reid WG, Trafficante R (2005) Sydney Multicenter Study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 20(2):190–199. https://doi.org/10.1002/mds.20324
Huot P, Johnston TH, Darr T, Hazrati LN, Visanji NP, Pires D, Brotchie JM, Fox SH (2010) Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov Disord 25(10):1399–1408
Huot P, Johnston TH, Gandy MN, Reyes MG, Fox SH, Piggott MJ, Brotchie JM (2012a) The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset. PLoS ONE 7(9):e45587. https://doi.org/10.1371/journal.pone.0045587
Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM (2012b) L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson’s disease. Neuropharmacology 63(5):829–836. https://doi.org/10.1016/j.neuropharm.2012.06.012
Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM (2013) The pharmacology of L-DOPA-induced dyskinesia in Parkinson’s disease. Pharmacol Rev 65(1):171–222. https://doi.org/10.1124/pr.111.005678
Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM (2011) Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, Whereas S-MDMA extends duration of ON-time. J Neurosci 31(19):7190–7198. https://doi.org/10.1523/JNEUROSCI.1171-11.2011
Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM (2014) UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset. Neuropharmacology 82:76–87. https://doi.org/10.1016/j.neuropharm.2014.01.012
Jenner P (2008) Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 9(9):665–677. https://doi.org/10.1038/nrn2471
Johnson MP, Barda D, Britton TC, Emkey R, Hornback WJ, Jagdmann GE, McKinzie DL, Nisenbaum ES, Tizzano JP, Schoepp DD (2005) Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology 179(1):271–283. https://doi.org/10.1007/s00213-004-2099-9
Johnson PL, Fitz SD, Engleman EA, Svensson KA, Schkeryantz JM, Shekhar A (2013) Group II metabotropic glutamate receptor type 2 allosteric potentiators prevent sodium lactate-induced panic-like response in panic-vulnerable rats. J Psychopharmacol 27(2):152–161. https://doi.org/10.1177/0269881112454230
Kwan C, Frouni I, Bedard D, Nuara SG, Gourdon JC, Hamadjida A, Huot P (2019) 5-HT2A blockade for dyskinesia and psychosis in Parkinson’s disease: is there a limit to the efficacy of this approach? A study in the MPTP-lesioned marmoset and a literature mini-review. Exp Brain Res 237(2):435–442. https://doi.org/10.1007/s00221-018-5434-9
Lees AJ, Ferreira J, Rascol O, Poewe W, Rocha JF, McCrory M, Soares-da-Silva P, Investigators B-S (2017) Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol 74(2):197–206. https://doi.org/10.1001/jamaneurol.2016.4703
Limapichat W, Yu WY, Branigan E, Lester HA, Dougherty DA (2013) Key binding interactions for memantine in the NMDA receptor. ACS Chem Neurosci 4(2):255–260. https://doi.org/10.1021/cn300180a
Lovinger DM, McCool BA (1995) Metabotropic glutamate receptor-mediated presynaptic depression at corticostriatal synapses involves mGLuR2 or 3. J Neurophysiol 73(3):1076–1083. https://doi.org/10.1152/jn.1995.73.3.1076
Nuara SG, Hamadjida A, Gourdon JC, Huot P (2020a) The mGlu2/3 antagonist LY-341,495 reverses the anti-dyskinetic and anti-psychotic effects of the mGlu2 activators LY-487,379 and LY-354,740 in the MPTP-lesioned marmoset. J Neural Transm (Vienna) 127(7):1013–1021. https://doi.org/10.1007/s00702-020-02196-w
Nuara SG, Hamadjida A, Kwan C, Bedard D, Frouni I, Gourdon JC, Huot P (2020b) Combined mGlu2 orthosteric stimulation and positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the parkinsonian marmoset. J Neural Transm (Vienna) 127(7):1023–1029. https://doi.org/10.1007/s00702-020-02185-z
Pahwa R, Hauser RA (2017) ADS-5102 (Amantadine) Extended release for levodopa-induced dyskinesia. JAMA Neurol 74(12):1507–1508. https://doi.org/10.1001/jamaneurol.2017.3205
Pahwa R, Tanner CM, Hauser RA, Sethi K, Isaacson S, Truong D, Struck L, Ruby AE, McClure NL, Went GT, Stempien MJ (2015) Amantadine extended release for levodopa-induced dyskinesia in Parkinson’s disease (EASED Study). Mov Disord 30(6):788–795. https://doi.org/10.1002/mds.26159
Parent A, Sato F, Wu Y, Gauthier J, Levesque M, Parent M (2000) Organization of the basal ganglia: the importance of axonal collateralization. Trends Neurosci 23(10 Suppl):S20-27
Parkinson Study Group (1999) Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. The Parkinson Study Group. N Engl J Med 340(10):757–763
Perez-Lloret S, Rascol O (2018) Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia. J Neural Transm (Vienna). https://doi.org/10.1007/s00702-018-1869-1
Picconi B, Pisani A, Centonze D, Battaglia G, Storto M, Nicoletti F, Bernardi G, Calabresi P (2002) Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment. Brain 125(Pt 12):2635–2645
Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M (2002) Efficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 105(4):245–255
Postma JU, Van Tilburg W (1975) Visual hallucinations and delirium during treatment with amantadine (Symmetrel). J Am Geriatr Soc 23(5):212–215
Schapira AH, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, Kulisevsky J, Pahwa R, Poewe W, Anand R (2017) Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol 74(2):216–224. https://doi.org/10.1001/jamaneurol.2016.4467
Schrag A (2005) Entacapone in the treatment of Parkinson’s disease. Lancet Neurol 4(6):366–370. https://doi.org/10.1016/S1474-4422(05)70098-3
Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, Weintraub D, Sampaio C, the collaborators of the Parkinson’s Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine C (2019) Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Mov Disord 34(2):180–198. https://doi.org/10.1002/mds.27602
Sgambato-Faure V, Cenci MA (2012) Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson’s disease. Prog Neurobiol 96(1):69–86. https://doi.org/10.1016/j.pneurobio.2011.10.005
Sid-Otmane L, Hamadjida A, Nuara SG, Bedard D, Gaudette F, Gourdon JC, Michaud V, Beaudry F, Panisset M, Huot P (2020) Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset. Eur J Pharmacol 873:172957. https://doi.org/10.1016/j.ejphar.2020.172957
Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M (2004) Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease. J Neurol Neurosurg Psychiatry 75(1):141–143
Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, Del Tredici AL, Piu F, Schiffer HH, Ott TR, Burstein ES, Uldam AK, Thygesen MB, Schlienger N, Andersson CM, Son TY, Harvey SC, Powell SB, Geyer MA, Tolf BR, Brann MR, Davis RE (2006) Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N’-(4-(2-methylpropylo xy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther 317(2):910–918. https://doi.org/10.1124/jpet.105.097006
Veyres N, Hamadjida A, Huot P (2018) Predictive value of Parkinsonian primates in pharmacologic studies: a comparison between the Macaque, Marmoset, and Squirrel Monkey. J Pharmacol Exp Ther 365(2):379–397. https://doi.org/10.1124/jpet.117.247171
Visanji NP, Gomez-Ramirez J, Johnston TH, Pires D, Voon V, Brotchie JM, Fox SH (2006) Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson’s disease. Mov Disord 21(11):1879–1891. https://doi.org/10.1002/mds.21073
Zhang J, Qu FR, Nakatsuka A, Nomura T, Nagai M, Nomoto M (2003) Pharmacokinetics of L-dopa in plasma and extracellular fluid of striatum in common marmosets. Brain Res 993(1–2):54–58
Funding
IF holds a scholarship from Parkinson Canada. CK has held a scholarship from Parkinson Canada and holds a scholarship from Fonds de Recherche Québec—Santé. PH has received research support from Parkinson Canada, Parkinson Québec, Fonds de Recherche Québec—Santé, the Weston Brain Institute, the Michael J Fox Foundation for Parkinson’s Research, the Natural Sciences and Engineering Research Council of Canada and Healthy Brains for Healthy Lives.
Author information
Authors and Affiliations
Contributions
SGN, JCG, PH conceived and designed research. IF, CK, SGN, SB, WK, AH, DB conducted experiments. PH analysed data. PH wrote the manuscript.
Corresponding author
Ethics declarations
Ethics approval
Experiments were approved by McGill University and the Montreal Neurological Institute Animal Care Committees, which are in accordance with the regulations defined by the Canadian Council on Animal Care.
Informed Consent
All authors read, commented on, and approved the manuscript.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Frouni, I., Kwan, C., Nuara, S.G. et al. Effect of the mGlu2 positive allosteric modulator CBiPES on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset. J Neural Transm 128, 73–81 (2021). https://doi.org/10.1007/s00702-020-02287-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-020-02287-8